Company
Daiichi Sankyo
Daiichi Sankyo has 35 drugs tracked on RxWires: 3 post-market, 1 approved, 8 in Phase 3, 7 in Phase 2, 4 in Phase 1/2, 12 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| olmesartan medoxomil | Post-Market | Hypertension |
| olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary | Post-Market | Essential Hypertension |
| Prasugrel Loading Dose | Post-Market | Coronary Artery Disease |
| DATROWAY | Approved | |
| Rivoglitazone HCl | Phase 3 | Type 2 Diabetes Mellitus |
| Trastuzumab Deruxtecan | Phase 3 | Endometrial Cancer |
| DS-5565 | Phase 3 | Diabetic Peripheral Neuropathic Pain |
| Colesevelam hydrochloride | Phase 3 | Type 2 Diabetes |
| exatecan mesylate | Phase 3 | Pancreatic Cancer |
| Edoxaban | Phase 3 | CTEPH |
| CS8635 20/5/12.5mg and placebo | Phase 3 | Essential Hypertension |
| Datopotamab Deruxtecan | Phase 3 | Metastatic Non Small Cell Lung Cancer |
| DU-176b | Phase 2 | Arthroplasty, Replacement, Hip |
| CS-1008 | Phase 2 | Non-small Cell Lung Cancer |
| Valemetostat Tosylate | Phase 2 | Relapsed/Refractory Peripheral T-Cell Lymphoma |
| Patritumab Deruxtecan (Fixed dose) | Phase 2 | Non-Small Cell Lung Cancer Metastatic |
| CS-3150 | Phase 2 | Hypertension |
| DS-8500a 25 mg | Phase 2 | Type 2 Diabetes Mellitus |
| efatutazone | Phase 2 | Liposarcoma |
| DS-1103a | Phase 1/2 | Solid Tumor |
| Tivantinib | Phase 1/2 | Malignant Solid Tumour |
| DS-1040b | Phase 1/2 | Pulmonary Embolism |
| Ifinatamab deruxtecan (I-DXd) | Phase 1/2 | Advanced Solid Tumor |
| DS-1971a | Phase 1 | Healthy |
| HER3-DXd (FL-DP) | Phase 1 | Non-Small Cell Lung Cancer (NSCLC) |
| DS-7309 | Phase 1 | Type 2 Diabetes Mellitus |
| AC220 | Phase 1 | Leukemia, Myeloid, Acute |
| DS-8201a (DP1) | Phase 1 | Advanced Solid Tumors |
| Quizartinib | Phase 1 | Healthy Subjects |
| AMP-110 | Phase 1 | Rheumatoid Arthritis |
| Patritumab | Phase 1 | Squamous Cell Carcinoma of the Head and Neck |
| DS-3032b | Phase 1 | Myeloma |
| U3 1402 | Phase 1 | Breast Cancer |
| DS1025a | Phase 1 | Advanced Solid Tumor |
| DS-3201b | Phase 1 | Hepatic Impairment |
Latest
No recent events.
Follow Daiichi Sankyo on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.